| Net income | -13.58M |
| Depreciation and amortization | |
| Exchange (gain) loss | 0 |
| Deferred taxes | |
| Restructuring | |
| Gain on sale of CNS assets | |
| Stock-based compensation | 1.09M |
| Restricted Cash | |
| Accounts receivable | 2.72M |
| Inventory | 820K |
| Prepaid expenses and other current assets | |
| Other assets and liabilities | 15K |
| Deferred revenue | -131K |
| Accounts payable and accrued expenses | -4.8M |
| Accrued compensation | -1.11M |
| Net cash provided by (used in) operating activities | -7.99M |
| Sales of investments | |
| Purchases of investments | |
| Purchases of property and equipment | -498K |
| Proceeds from sale of CNS assets | |
| Net cash provided by (used in) investing activities | 10.06M |
| Purchases of treasury stock | -141K |
| Proceeds from stock options exercised | |
| Net cash provided by (used in) financing activities | -316K |
| Effect of exchange rate changes on cash | -3K |
| Net increase in cash | 1.75M |
| Cash and cash equivalents, beginning of period | 19.17M |
| Cash and cash equivalents, end of period | 20.92M |